Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukaemia and lymphoma.
The potential long-term toxicity of central nervous system prophylaxis (CNS-P) in adult acute lymphoblastic leukaemia (ALL, n = 17) and non-Hodgkin's lymphoma (NHL, n = 7) was investigated in a multidisciplinary study. At least 4 years had elapsed from CNS-P (mean 11.5 years) for all patients. Neurological history and physical examination were unremarkable; minor signs were commoner in older patients (P less than 0.02). Psychometry yielded normal results, but individual verbal IQ generally exceeded performance IQ, with a trend to more marked differences in younger adults (P = 0.06). EEG was scored and differed significantly from that of controls, with a tendency to more marked (but still minor) abnormalities in younger patients (P = 0.06). Brainstem auditory evoked potentials demonstrated significant but generally minor abnormality in 24% of patients. CT brain scan revealed widening of cerebral hemisphere sulci to greater than 3 mm in 38% of patients; cerebral atrophy was commoner in the older group (P less than 0.02) and those with neurological signs (P less than 0.02). MRI brain scans were normal in all patients tested. Thus, following standard CNS-P for ALL at this hospital, there is a 5% primary CNS relapse rate, and only minimal, mainly subclinical, long-term neuropsychological toxicity.
Tucker
J
J
ICRF Dept of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London, UK.
Prior
P F
PF
Green
C R
CR
Ede
G M
GM
Stevenson
J F
JF
Gawler
J
J
Jamal
G A
GA
Charlesworth
M
M
Thakkar
C M
CM
Patel
P
P
D000328:Adult; D000368:Aged; D001921:Brain / Q000187:drug effects / Q000528:radiation effects; D001932:Brain Neoplasms / Q000517:prevention & control*; D003131:Combined Modality Therapy; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007361:Intelligence Tests; D008228:Lymphoma, Non-Hodgkin / Q000503:physiopathology / Q000523:psychology*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D009483:Neuropsychological Tests; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000503:physiopathology / Q000523:psychology*; D011882:Radiotherapy, High-Energy / Q000009:adverse effects*; D013120:Spinal Cord Neoplasms / Q000517:prevention & control*
D008727:Methotrexate